Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial

Journal of International Medical Research

Volumn 28, Issue 2, 2000, Pages 47-68

  Insull Jr , W ^a   Isaacsohn, J ^b   Kwiterovich, P ^c   Ma, P ^d   Brazg, R ^e   Dujovne, C ^f   Shan, M ^g   Shugrue Crowley, E ^g   Ripa, S ^g   Tota, R ^g  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b Metabolic and Atherosclerosis Research Center   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Heart Health Institute   (Canada)

^e Ranier Clinical Research Center   (United States)

^f RADIANT RESEARCH   (United States)

^g BAYER CORPORATION   (United States)

Author keywords

Cerivastatin; HMG CoA reductase inhibitors; Hypercholesterolaemia; Low density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LEG CRAMP; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYASTHENIA; NAUSEA; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

EID: 0343963060     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000002800201     Document Type: Article

References (41)

1. Castelli WP, Anderson K, Wilson PW, et al: Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992; 2: 23-28.
2. Neaton JD, Blackburn H, Jacobs D, et al: Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490-1500.
3. LaRosa JC, Hunninghake D, Bush D, et al: The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81: 1721-1733.
4. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary artery disease. JAMA 1984; 251: 351-364.
5. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
6. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
7. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
8. Sacks FM, Pfeffer MA, Move LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335; 1001-1009.
9. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023.
11. Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care 1998; 21: 179-182.
12. Bischoff H, Angerbauer R, Bender J, et al: Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997; 135: 119-130.
13. Davignon J, Hanefeld M, Nakaya N, et al: Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Am J Cardiol 1998; 82: 32J-39J.
14. Stein E: Cerivastatin in primary hyperlipidemia - a multicenter analysis of efficacy and safety. Atherosclerosis 1998; 139 (Suppl 1): S15-S22.
15. Ose L, Luurila O, Erikson J, et al: Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolemia: a multinational, randomised, double-blind study. Curr Med Res Opin 1999; 15: 228-240.
16. Stein E, Isaacsohn J, Stoltz R, et al: Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Am J Cardiol 1999; 83: 1433-1436.
17. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
18. Stein E: Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol 1998; 82: 40J-46J.
19. Roberts WC: The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80: 106-107.
20. Hunninghake D, Dujovne C, Stein E, et al: The 0.4 mg dose of cerivastatin: comparative safety and efficacy of cerivastatin 0.3 mg versus fluvastatin 40 mg. Pharmacotherapy 1999; 19: 1194.
21. Dujovne C, Kwiterovich P, Hunninghake D, et al: Comparison of cerivastatin 0.3 mg to pravastatin 20 mg, and cerivastatin 0.4 mg to pravastatin 40 mg in 1030 hypercholesterolemic patients. Pharmacotherapy 1999; 19: 1193.
22. Hanefeld M, Deslypere JP, Ose L, et al: Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study. J Int Med Res 1999; 27: 115-129.
23. Bucher HC, Griffith LE, Guyatt GH: Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 187-195.
24. Gould AL, Rossouw JE, Santanello NC, et al: Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-952.
25. Eisenberg DA: Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med 1998; 104: 2S-5S.
26. Hunninghake DB: Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. Am J Med 1998; 104: 9S-13S.
27. Assmann G, Schulte H, Funke H, et al: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998; 19 (Suppl M): M8-M14.
28. Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B-69B.
29. Nawrocki JW, Weiss SR, Davidson MH, et al: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-682.
30. Bradford RH, Shear CL, Chremos AN, et al: Expanded clinical evaluation of lovastatin [EXCEL] study results: two-year efficacy and safety follow-up. Am J Cardiol 1994; 74: 667-673.
31. Grundy SM: Consensus statement: role of therapy with 'statins' in patients with hypertriglyceridemia. Am J Cardiol 1998; 81: 1B-6B.
32. Dujovne CA: New lipid lowering drugs and new effects of old drugs. Curr Opin Lipidol 1997; 8: 362-368.
33. Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83: 25F-29F.
34. Vaisanen S, Gavert J, Julkunen A. et al: Correlation between the ratio of serum low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with that of serum apolipoproteins B and A-I. Int J Clin Lab Res 1993; 23: 160-164.
35. Cubero GI, Reguero JJ, Batalla A, et al: Plasma lipids, HDL and apolipoproteins, and coronary heart disease in men less than 50 years old. A case-control study. Acta Cardiol 1998; 53: 269-273.
36. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-75.
37. Yee HS, Fong NT: Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother 1998; 32: 1030-1043.
38. Bradford RH, Shear CL, Chremos AN, et al: Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-49.
39. Bradford RH, Downton M, Chremos AN, et al: Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med 1993; 118: 850-855.
40. Pogson GW, Kindred LH, Carper BG: Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999; 83: 1146.
41. Nakad A, Bataille L, Hamoir V, et al: Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 1999; 353: 1763-1764.